A Phase 3 interventional study of navenibart and Placebo in Hereditary Angioedema (HAE), sponsored by Astria Therapeutics, Inc.. Active, not recruiting at 86 sites in 24 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by Astria Therapeutics, Inc. (part of BioCryst Pharmaceuticals) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals — 2 open to participants now, 5 under way, 4 of them phase 3. Angioedemas, Hereditary · BioCryst Pharmaceuticals.
Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, this one is the 2nd largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2025, is one of 7 in phase 3, and was the 21st registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →2 of the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:
Astria Therapeutics, Inc. · Sites in United States, Brazil, Bulgaria and 15 more countries
Ages 12+
BioCryst Pharmaceuticals · Sites in Canada, Czechia, France and 8 more countries
Ages 2+
By country, each count listing its studies:
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 7 · Phase 3 9
First in 2013; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 157 is above the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 54 across the 21 interventional studies. Of the 16 that completed or were terminated, 7 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Astria Therapeutics, Inc., one of the names counted as BioCryst Pharmaceuticals. Under that name alone:
Astria Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
1 of the studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06842823Phase 3Astria Therapeutics, Inc.A Study of Navenibart in Participants With Hereditary Angioedema | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Angioedemas, Hereditary by BioCryst Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented diagnosis of HAE (Type 1 or 2). The following must be met:
Exclusion Criteria:
Use of therapies prescribed for the prevention of HAE attacks may not be used during the trial or within the below time frames prior to the Run-In Period (adult participants may be on these medications at the time of the Screening Visit, but will need to prior to entering the Run-In Period).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 600 mg of navenibart every 3 months.
Drug: navenibart
Participants will receive 600 mg of navenibart on Day 1 and 300 mg every 3 months starting at month 3.
Drug: navenibart
Participants will receive 600 mg of navenibart every 6 months.
Drug: navenibart
Participants will receive placebo every 3 months.
Drug: Placebo
Participants will receive 600 mg of navenibart on Day 1 and 300 mg every 3 months starting at month 3.
Drug: navenibart
Navenibart will be administered as a subcutaneous injection.
Also known as: STAR-0215
Placebo will be administered as a subcutaneous injection.
Number of time-normalized investigator-confirmed HAE attacks during the 6-month Treatment Period.
Time frame: Day 1 through Day 181
Number of moderate or severe investigator-confirmed HAE attacks during the 6-month Treatment Period.
Time frame: Day 1 through Day 181
Number of investigator-confirmed HAE attacks that require on-demand treatment during the 6-month Treatment Period.
Time frame: Day 1 through Day 181
Percent reduction in monthly investigator-confirmed HAE attacks in the 6-month Treatment Period versus the Run-In Period.
Time frame: Baseline through Day 181
Time to first investigator-confirmed HAE attack after first and second dose.
Time frame: Day 1 through Day 181
The number of participants responding to treatment, defined as a ≥ 50%, ≥ 70%, or ≥ 90% reduction from the Run-In Period in investigator-confirmed HAE attack rate (for adult participants: compared to placebo during the 6-month Treatment Period).
Time frame: Baseline through Day 181
Number of participants with no investigator-confirmed HAE attacks during the 6-month Treatment Period.
Time frame: Day 1 through Day 181
Change from baseline (Day 1) in the Angioedema Quality of Life questionnaire total score.
Time frame: Day 1 through Day 181
Incidence of treatment-emergent adverse events.
Time frame: Day 1 through Day 361
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.
Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's planned 21 months is close to that.
Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Navenibart